Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma

Why It Matters

These emerging regimens could redefine first‑line standards for DLBCL and Richter transformation, offering potential efficacy gains while demanding careful safety management and confirmatory randomized data.

Key Takeaways

• Pola‑R‑CHP improves PFS vs R‑CHOP, especially ABC subtype
• Bispecific antibodies + chemo show comparable PFS, higher toxicity
• Randomized data lacking for BsAb‑chemo combos; safety monitoring essential
• Venetoclax‑based regimens show activity in Richter transformation
• CRS and neutropenia remain major adverse events in new combos

Pulse Analysis

Diffuse large B‑cell lymphoma remains the most common aggressive non‑Hodgkin lymphoma, and R‑CHOP has been the backbone of curative therapy for decades. However, roughly 40% of patients relapse, prompting investigators to integrate novel agents such as polatuzumab vedotin and CD3×CD20 bispecific antibodies into frontline protocols. By substituting vincristine with polatuzumab, the POLARIX trial achieved a statistically significant progression‑free survival advantage, especially among patients with ABC‑type disease and those over 60, positioning Pola‑R‑CHP as a credible alternative to R‑CHOP in selected cohorts.

Parallel efforts have explored bispecific antibody‑chemotherapy hybrids, including mosunetuzumab‑CHOP/Polatuzumab‑CHP and glofitamab‑R‑CHOP/Polatuzumab‑R‑CHP. Early-phase data reveal progression‑free survival rates that approximate standard regimens, yet the safety profile is less forgiving. Grade 3/4 neutropenia, febrile neutropenia, and cytokine‑release syndrome (CRS) occur at markedly higher frequencies, underscoring the need for rigorous patient selection and prophylactic strategies. The absence of large, randomized head‑to‑head trials means clinicians must weigh modest efficacy signals against amplified toxicity when considering these combinations.

Richter transformation, an aggressive evolution of chronic lymphocytic leukemia, lacks an established frontline standard. Recent studies combining venetoclax with dose‑adjusted EPOCH or R‑CHOP have produced response rates exceeding 60% and median overall survivals approaching two years, albeit with significant hematologic toxicity. Antibody‑based triplets that add checkpoint inhibition or bispecific agents further expand the therapeutic arsenal, offering chemotherapy‑free pathways for a subset of patients. As these regimens mature, ongoing trials will clarify optimal sequencing, combination ratios, and supportive care measures, ultimately shaping future guidelines for both DLBCL and its Richter variant.